AbbVie posted higher fourth-quarter revenue on the back of growth from its immunology portfolio, led by arthritis and Crohn’s disease drugs Skyrizi and Rinvoq.
Source link
AbbVie Revenue Rises on Immunology Growth
Date:
More like thisRelated
2026 MLB trade deadline tracker: Rumors, news, analysis
Jul 26, 2026, 10:10 AM ETThe 2026 MLB trade...
Berlin Pride ramming attack believed to be act of Islamist extremist terror as hunt for suspect continues
The car ramming attack on...
Kacey Musgraves Cancels Three Shows, No Reason Given
Kacey Musgraves has canceled three dates on her upcoming Middle of...